ADGI ADAGIO THERAPEUTICS INC

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences:

Cantor Global Healthcare Conference 2025

Fireside Chat Date: Wednesday, September 3, 2025

Fireside Chat Time: 2:10 PM ET

Location: New York, NY

H.C. Wainwright 27th Annual Global Investment Conference

Fireside Chat Date: Monday, September 8, 2025

Fireside Chat Time: 12:00 PM ET

Location: New York, NY

Live webcasts of the fireside chats will be available in the investor section of the company’s website at and will be archived for approximately 30 days following each event.

In addition to the fireside chats, the management team will host investor meetings at the conferences. Investors participating in the conferences who are interested in meeting with Invivyd management should contact their Cantor or H.C. Wainwright representative.

About Invivyd



Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit / to learn more.

Contacts:

Media Relations

(781) 208-1747

Investor Relations

(781) 208-1747



EN
27/08/2025

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd to Participate in Upcoming Investor Conferences

Invivyd to Participate in Upcoming Investor Conferences WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will present at the following investor conferences: Cantor Global Healthcare Conference 2025Fireside Chat Date: Wednesday, September 3, 2025Fireside Chat Time: 2:10 PM ETLocation: New York, NY H.C. Wainwright 27th Annual Global Investment ConferenceFireside Chat Date: Monday, September 8, 2025Fireside Chat Time: 12:00 PM ETLocation: New York, NY Live webcasts of the fireside chats will be available in the investor section o...

22h / 54m 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Closing of $57.5 Million Public Offering and Full Ex...

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full by the underwriter of its option to purchase an additional 14,423,076 shares of common stock, at a public offering price of $0.52 per share and pre-funded warrants to purchase 21,342,442 shares of its common ...

August 22, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Pricing of $50 Million Public Offering of Common Sto...

Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre-funded warrants to purchase 21,342,442 shares of its common stock at a price of $0.5199 per pre-funded warrant. The gross proceeds from this offering are expected to be approximately $50.0 million, before dedu...

August 21, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Proposed Public Offering of Common Stock

Invivyd Announces Proposed Public Offering of Common Stock WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of Invivyd common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Invivyd. The offering is subject to marke...

August 20, 2025 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivi...

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”) New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG variant appears to be driving a growing wave of COVID-19 in AmericaVYD2311 in vitro neutralization data demonstrate similarly consistent and highly potent results against XFGSimilar new, positive in vitro neutralization data for pemivibart and VYD...

August 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch